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Abstract 
1,4-dihydropyridine derivatives represent one of the important classes of compounds possessing a wide variety 
of biological activities including anticancer activity. In the present study, (4-Alkyl/Aryl-1-substituted 2,6-
dimethyl-1,4-dihydropyridine-3,5-dicarboxilicacid, 3,5-bis [2(aminothioxomethyl)hydrazides]) (6 a-l) were 
synthesized by the reaction of 4-alkyl/aryl-3,5-dicarboalkoxy-2,6-dimethyl-1,4-dihydropyridines (4 a-l) with 
thisemicarbazide and evaluated for their anti-cancer properties.  
All the synthesized compounds were characterized by IR, NMR and Mass spectra and were screened to 
evaluating for anticancer activity against three cell lines (MCF-7, HeLa and Hep G2) by using MTT assay 
method. The results showed that compounds 6j and 6l showed significant cytotoxicity with IC50 values ranging 
from 56µM - 74µM. 
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1. Introduction  
Chemotherapy plays an important role in the treatment of several cancers including breast cancer. However, 
during treatment with chemotherapeutic agents, the development of drug resistance is quite common in the 
metastatic cancers [1, 2]. After intermittent or prolonged exposure of tumor cells to only a single agent is often 
found to result in broad resistance to multiple structurally and functionally unrelated drugs [3]. Due to the 
development of multidrug resistance in cancer chemotherapy, necessity for effective therapy stimulated search 
for design and synthesis of newer agents. Hantzsch 1,4-dihydropyridines (1,4-DHPs) and their derivatives have 
acquired great importance in the area of organic and medicinal chemistry since they exhibit a fascinating array 
of pharmacological properties like antihypertensive [4,5], antimicrobial [6,7], anti-tubercular[8,9], 
antileishmanial [10, 11], antidyslipidemic [12] and cytotoxic activities [13,14]. 1,4-Dihydropyridines are 
commercially used as calcium channel blockers for the treatment of cardiovascular diseases. It is quite 
interesting to note that the 1,4-DHPs have gained prominence in the recent years for cancer chemotherapy, in 
addition to their calcium channel blocking action. 1,4-Dihydropyridines have been proved to be a new class of 
multidrug resistance (MDR) reversals in cancer treatment. Our team has been working in this area for the 
development of new 1,4-dihydropyridines as MDR reversal agents apart from anti-cancer and antitubercular 
activities [15-20]. Thosemicarbazide and semicarbazide derivatives have been documented as potential 
antibacterial, antifungal and antitubercular agents [21, 22]. Thiosemicarbazide derivatives were also reported to 
have significant antitumor [23, 24], anticoagulant [25] and antiviral properties [26]. 
In view of the wide range of biological properties associated with 1,4-dihydropyridines  and thiosemicarbazide 
derivatives as anticancer agents, it was thought worthwhile to synthesize new molecules by incorporating 
thisemicarbazide and cyclohexyl/benzyl substitution with 1,4-dihydropyridines moieties in a single molecular 
framework and to evaluate their cytotoxic and antimicrobial activities. 
2. Materials and Methods 
Synthesis of all the compounds was carriedout by using Redleys reaction station.  Melting points were 
determined in one-end-open capillary tubes on Toshniwal melting point apparatus and are uncorrected. IR 
spectra in KBr discs recorded on Perkin-Elmer BX-I series FT-IR spectrophotometer and 1H NMR on a Bruker 
AVANCE-300 spectrometer. All NMR spectra were measured in CDCl3 solution using tetra methylsilane as an 
internal standard and 1H chemical shifts are reported as ppm. Mass spectra were recorded by using electro spray 
ionization technique (ESI) on the VG170708H mass spectrometer. Solvents were dried by conventional 
methods. Silica gel 60-120 mesh (Merck) was used as an adsorbent for column chromatography. TLC was 
performed on 5 –10 cm aluminum plates coated with silicagel 60F-254 (Merck) in an appropriate solvent. 
2.1. Experiemental 
2.1.1.  4-Alkyl/Aryl-1-substituted-3,5-bis(carboethoxy)-2,6-dimethyl-1,4-dihydropyridines 
To the mixture of ethyl acetoacetate and different aliphatic and aromatic aldehydes in alcohol was added a 
solution of primary amine with shaking and the mixture was refluxed for 12 to 16 hours. Upon completion of 
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the reaction, alcohol was removed to the possible extent by rota evaporator and the residue was cooled and 
triturated with crushed ice, and thus resultant precipitate was filtered and washed with cold water and dried in 
vacuum. 
2.1.2. 4-Alkyl/Aryl-1-substituted-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxilicacid-3,5-bis[2 (amino- -
 thioxomethyl)hydrazide] 
A reaction mixture consisting of compound (4 a-l, 0.1 mol), thiosemicarbazide (0.2 mol) dissolved in ethanol 
(30 mL) and a few drops of DMSO was added. It was then heated under reflux for 10 h. The reaction mixture 
was cooled and then poured in to crushed ice. The separated solid was collected by filtration, washed with water 
and recrystallised using ethanol. 
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Figure 1: Scheme for the synthesis of 1,4-Dihydropyridine thiosemicarbazide derivatives. 
 
2.2. Anticancer activity 
Anticancer activity of the all the synthesized compounds was assessed by their cytotoxic effect against three 
cancer cell lines MCF-7, Hela, and Hep G2 (purchased from NCCS, Pune)   using MTT assay method described 
by Mosmann and his colleagues [27]. The cells were grown in RPMI medium containing 10% FBS in 
humidified atmosphere of 5% CO2 at 37 oC. Cells were trypsinized and seeded in 96 well plates at a density of 
5000 cells per well and incubated for 24 hours to get monolayer of cells. Serial concentrations of compounds 
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were made with RPMI media using DMSO as co-solvent. After 24 hours the test molecules of various 
concentrations in fresh media were added to appropriate wells. Plates were incubated further for 48 hours and 
the assay was quenched 20 µl of (Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 5 mg/ml) and 
incubated for 60 min at 37oC. The plates were dried and subsequently the dye bound to the cells was solubilised 
in 100 µl of DMSO. The spectrophotometric absorbance of the samples was observed using a microplate 
(ELISA) reader. The wavelength to measure absorbance of the formazan product was 570 nm on the ELISA 
reader (Thermo, USA). 
3. Characterization  
3.1. 2,2'-(1-cyclohexyl-2,6-dimethyl-4-phenyl-1,4-dihydropyridine-3,5-dicarbonyl)   
bis(hydrazinecarbothioamide) (6a) 
IR (KBr, cm-1): 3218 (NH2), 3196(NH), 3043 (C-H aromatic), 1761 (C=O, Carbonyl); 1H NMR (DMSO – d6) δ 
ppm: 0.97-1.27 (s, 10H, Cyclohexyl), 2.28 (s, 6H, C2-CH3 and C6-CH3), 4.90 (s, 1H, C4-H), 7.07-7.18 (m, 3H, 
phenyl) 7.20-7.27 (m, 2H, Phenyl), 8.63(s,1H, CO-NH), 8.94 (s, 2H, NH2); MS (ESI): m/z: 502 [M+1]+. 
3.2. 2,2'-(1-cyclohexyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarbonyl) 
bis(hydrazinecarbothioamide) (6b) 
IR (KBr, cm-1): 3212 (-NH2), 3175(NH), 3056 (C-H aromatic), 1720 (C=O, Carbonyl); 1H NMR (DMSO – d6) 
δ ppm: 1.05-1.24 (m, 10H, Cyclohexyl), 2.32(s, 6H, C2-CH3 and C6-CH3), 5.01(s, 1H, C4-H), 9.07 (s, 2H, 
NH2), 7.52-7.70 (m, 4H, Phenyl), 9.06 (s, 2H, NH2); MS (ESI): m/z: 547 [M+1]+. 
3.3. 2,2'-(1-cyclohexyl-4-(4-methoxyphenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5dicarbonyl) 
bis(hydrazinecarbothioamide). (6c) 
IR (KBr, cm-1): 3231 (-NH2), 3198(NH), 3034 (C-H aromatic), 1698 (C=O, Carbonyl); 1H NMR (DMSO – d6) 
δ ppm: 1.03-1.16 (m, 10H, Cyclohexyl), 2.25 (s, 6H, C2-CH3 and C6-CH3), 3.65 (s, 3H, OCH3), 4.78(s, 1H, C4-
H), 6.70-6.78(d, 2H, Aromatic), 7.01-7.08(d, 2H, Aromatic), 8.62(s, 1H, CO-NH), 8.85(s, 2H, NH2); MS (ESI): 
m/z: 532 [M+1]+. 
3.4. 2,2'-(1-cyclohexyl-2,6-dimethyl-4-(p-tolyl)-1,4-dihydropyridine-3,5-dicarbonyl) 
bis(hydrazinecarbothioamide). (6d) 
(KBr, cm-1): 3224 (-NH2), 3180 (NH), 3064 (C-H aromatic), 1710 (C=O, Carbonyl);1H NMR (DMSO – d6) δ 
ppm: 0.99-1.27 (m, 10H, Cyclohexyl), 2.17 (s, 6H, C2-CH3 and C6-CH3), 3.17 (s, 3H, -CH3), 4.89 (s, 1H, C4-
H), 7.12-7.64(m, 5H, Aromatic), 8.62(s, 2H, NH2); MS (ESI): m/z: 516 [M+1]+. 
3.5. 2,2'-(4-(4-chlorophenyl)-1-cyclohexyl-2,6-dimethyl-1,4-dihydropyridine-3,5-
 dicarbonyl)bis(hydrazinecarbothioamide) (6e)  
(KBr, cm-1): 3220 (-NH2), 3192 (NH), 3028 (C-H aromatic), 1698 (C=O, Carbonyl); 1H NMR (DMSO – d6) δ 
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ppm: 1.01-1.28 (m, 10H, Cyclohexyl), 2.30(s, 6H, C2-CH3 and C6-CH3), 4.89(s, 1H, C4-H), 7.14-7.20(d, 2H, 
Aromatic), 7.24-7.30(s, 2H, Aromatic), 8.67(s, 1H, -CO-NH ), 8.99(s, 1H, NH2). MS (ESI): m/z: 537 [M+1]+.  
3.6. 2,2'-(1-benzyl-2,6-dimethyl-4-propyl-1,4-dihydropyridine-3,5-dicarbonyl)    
bis(hydrazinecarbothioamide) (6f) 
(KBr, cm-1): 3224 (-NH2), 3180 (NH), 3064 (C-H aromatic), 1710 (C=O, Carbonyl);   1H NMR (DMSO – d6) δ 
ppm: 0.91-1.39 (m,7H, propyl), 2.26(s, 6H, C2-CH3 and C6-CH3), 3.17 (s, 2H, CH2-Benzyl), 3.67 (s, 3H, 
OCH3), 4.80(s, 1H, C4-H), 6.70-6.81(d, 2H, Aromatic), 7.00-7.11(m, 3H, Aromatic), 8.64(s, 1H, -CO-NH ), 
8.76(s, 2H, NH2). MS (ESI): m/z: 477 [M+1]+. 
3.7. 2,2'-(1-benzyl-4-butyl-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarbonyl)   
 bis(hydrazinecarbothioamide) (6g) 
(KBr, cm-1): 3277 (-NH2), 3175 (NH), 3029 (C-H aromatic), 1696 (C=O, Carbonyl);   1H NMR (DMSO – d6) δ 
ppm: 0.93-1.47 (m,9H, butyl), 2.27(s, 6H, C2-CH3 and C6-CH3), 3.19(s, 2H, CH2-Benzyl), 4.93(s, 1H, C4-H), 
7.13-7.84 (m, 5H, Aromatic), 8.63(s, 1H, -CO-NH ) 8.97(s, 2H, NH2). MS (ESI): m/z: 491 [M+1]+. 
3.8. 2,2'-(1-benzyl-2,6-dimethyl-4-phenyl-1,4-dihydropyridine-3,5-dicarbonyl)  
 bis(hydrazinecarbothioamide) (6h) 
(KBr, cm-1): 3226 (-NH2), 3147 (NH), 3098 (C-H aromatic), 1698 (C=O, Carbonyl);   1H NMR (DMSO – d6) δ 
ppm: 2.26 (s, 6H, C2-CH3 and C6-CH3), 3.15 (s, 2H, CH2-Benzyl),  4.89 (s, 1H, C4-H), 7.01-7.30 (m, 7H, 
aromatic) 7.20-7.27 (m, 3H, aromatic), 8.63 (s, 1H, CO-NH), 8.91 (s, 2H, NH2). MS (ESI): m/z: 510 [M+1]+. 
3.9. 2,2'-(1-benzyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarbonyl) 
bis(hydrazinecarbothioamide) (6i) 
(KBr, cm-1): 3220 (-NH2), 3192(NH), 3028 (C-H aromatic), 1698 (C=O, Carbonyl);   1H NMR (DMSO – d6) δ 
ppm: 2.27 (s, 6H, C2-CH3 and C6-CH3), 3.18 (s, 2H, CH2-Benzyl),  4.95 (s, 1H, C4-H), 6.69-6.81 (d, 2H,) 7.13-
7.48 (m, 5H, aromatic), 4.48-7.53(d, 1H,),  7.57-7.62 (d,1H,), 8.65 (s, 1H, CO-NH), 8.99 (s, 2H, NH2). MS 
(ESI): m/z: 555 [M+1]+. 
3.10. 2,2'-(1-benzyl-4-(4-methoxyphenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarbonyl) 
bis(hydrazinecarbothioamide) (6j) 
(KBr, cm-1): 3243 (-NH2), 3194 (NH), 3088 (C-H aromatic), 1705 (C=O, Carbonyl);   1H NMR (DMSO – d6) δ 
ppm: 2.24 (s, 6H, C2-CH3 and C6-CH3),3.17 (s, 2H, CH2-Benzyl),  3.66 (s, 3H, OCH3), 4.80 (s, 1H, C4-H), 
6.69-6.81 (d, 2H,) 7.00-7.11 (d, 2H,), 7.20-7.64 (m, 5H, Benzyl), 8.64 (s, 1H, CO-NH), 8.77 (s, 2H, NH2). MS 
(ESI): m/z: 540 [M+1]+. 
3.11. 2,2'-(1-benzyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarbonyl) 
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bis(hydrazinecarbothioamide) (6i) 
(KBr, cm-1): 3220 (-NH2), 3192(NH), 3028 (C-H aromatic), 1698 (C=O, Carbonyl);   1H NMR (DMSO – d6) δ 
ppm: 2.27 (s, 6H, C2-CH3 and C6-CH3), 3.18 (s, 2H, CH2-Benzyl),  4.95 (s, 1H, C4-H), 6.69-6.81 (d, 2H,) 7.13-
7.48 (m, 5H, aromatic), 4.48-7.53(d, 1H,),  7.57-7.62 (d,1H,), 8.65 (s, 1H, CO-NH), 8.99 (s, 2H, NH2). MS 
(ESI): m/z: 555 [M+1]+. 
3.12. 2,2'-(1-benzyl-4-(4-methoxyphenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarbonyl) 
bis(hydrazinecarbothioamide) (6j) 
(KBr, cm-1): 3243 (-NH2), 3194 (NH), 3088 (C-H aromatic), 1705 (C=O, Carbonyl);   1H NMR (DMSO – d6) δ 
ppm: 2.24 (s, 6H, C2-CH3 and C6-CH3),3.17 (s, 2H, CH2-Benzyl),  3.66 (s, 3H, OCH3), 4.80 (s, 1H, C4-H), 
6.69-6.81 (d, 2H,) 7.00-7.11 (d, 2H,), 7.20-7.64 (m, 5H, Benzyl), 8.64 (s, 1H, CO-NH), 8.77 (s, 2H, NH2). MS 
(ESI): m/z: 540 [M+1]+. 
3.13. 2,2'-(1-benzyl-2,6-dimethyl-4-(p-tolyl)-1,4-dihydropyridine-3,5-dicarbonyl)  
 bis(hydrazinecarbothioamide) (6k) 
(KBr, cm-1): 3251 (-NH2), 3192 (NH), 3056 (C-H aromatic), 1727 (C=O, Carbonyl);   1H NMR (DMSO – d6) δ 
ppm: 2.28 (s, 6H, C2-CH3 and C6-CH3), 3.21(s, 2H, CH2-Benzyl), 4.94 (s, 1H, C4-H), 7.11-7.19 (d, 4H,), 7.31-
7.64 (m, 5H, Benzyl), 8.63 (s, 1H, CO-NH), 8.81 (s, 2H, NH2). MS (ESI): m/z: 525 [M+1]+. 
3.14. 2,2'-(1-benzyl-4-(4-chlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarbonyl) 
bis(hydrazinecarbothioamide) (6l) 
(KBr, cm-1): 3259 (-NH2), 3136(NH), 3059 (C-H aromatic), 1693 (C=O, Carbonyl);   1H NMR (DMSO – d6) δ 
ppm: 2.26 (s, 6H, C2-CH3 and C6-CH3), 3.17 (s, 2H, CH2-Benzyl), 4.84 (s, 1H, C4-H), 7.08-7.17 (d, 2H,) 7.19-
7.28 (d, 2H,), 7.31-7.64 (m, 5H, Benzyl), 8.63 (s, 1H, CO-NH), 8.94 (s, 2H, NH2). MS (ESI): m/z: 544 [M+1]+. 
4. Results and Discussion 
A series of 2,2'-[(4-substituted)1-cyclohexyl/benzyl-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarbonyl)] 
bis(hydrazinecarbothioamides) were synthesized by the reaction of 4-Alkyl/Aryl-1-substituted-3,5-
bis(carboethoxy)-2,6-dimethyl-1,4-dihydropyridines with thiosemicarbazide. The physical data of the 
compounds were presented in Table-1. The IR spectrum (KBr pellet) of 6a-6l showed absorption band in 
between 3220-3277cm-1 (NH2). The stretching band was noticed at ~ 3136 cm-1 (-NH) while carbonyl group 
(C=O) stretching peak was found in between 1693-1761 cm-1. 1H NMR spectrum of compounds 6a-6l showed 
peak in the range of δ 8.62-9.07 due to NH2. The singlet peaks at ~ 5.1 and ~ 8.63 were assigned to 4-CH of 
DHP and CO-NH respectively. The mass spectrum of the compounds showed the molecular ion peak which 
confirms the molecular mass of the compounds. 
Among all the compounds tested, compound 6l with N-benzyl and 4-(4-chlorophenyl) substitution exhibited the 
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highest potency against MCF-7 and HeLa cell lines with IC50 values of 56.8 and 66.5 µM respectively. Whereas 
compound 6j showed highest potency against Hep G2 cell lines with IC50 of 68.3 µM. Replacement of 4-(4-
chlorophenyl) group with N-butyl and N-propyl (6f and 6g) resulted in significant decrease in potency against 
MCF-7 and HeLa cell lines (IC50 values of 6f: ˃ 100 µM against MCF-7 and HeLa ) and (IC50 values of 6g 
86.2 and ˃ 100 µM against MCF-7 and HeLa respectively).  1-Benzyl group appears to be contributing to the 
activity against all the three cell lines, as its replacement with cyclohexyl group resulted in significant decrease 
in potency. For example compound 6e with 4-(4-chlorophenyl) and 1-cyclohexyl substitution exhibited IC50 of 
81.7 µM, compared to 56.8 µM shown by its 1-benzyl analog (6l) against MCF-7 cell lines. Among the 1-
cyclohexyl substituted compounds (6a-6e), the compound 6e with 4-(4-chlorophenyl) substitution showed 
highest potency against all three cell lines (MCF-7, HeLa and HepG2) with IC50 values 81.7, 78.1 and 79.5 µM 
respectively. 
Table 1: Physical properties of new 1,4-dihydropyridine derivatives (6a-6l) 
COMPOUND -R R1 
MOLECULAR 
WEIGHT 
(gm/mole) 
MELTING 
POINT 
( OC) 
% 
YIELD 
6a -C6H5 Cyclohexyl 501 168-169 59.3 
6b -C6H4. NO2 -3 Cyclohexyl 546 211-214 61.6 
6c -C6H4. OCH3 -4 Cyclohexyl 531 201-204 63.2 
6d -C6H4. CH3 -4 Cyclohexyl 515 209-211 49.6 
6e -C6H4. Cl -4 Cyclohexyl 536 214-216 57.3 
6f -n-Pr Benzyl 476 201-204 63.7 
6g n-Bu Benzyl 490 195-197 52.8 
6h -C6H5 Benzyl 509 211-213 60.4 
6i -C6H4. NO2 -3 Benzyl 554 252-255 46.8 
6j -C6H4. OCH3 -4 Benzyl 539 240-242 55.7 
6k -C6H4. CH3 -4 Benzyl 523 218-221 61.6 
6l -C6H4. Cl -4 Benzyl 543 231-233 59.5 
 
5. Conclusion 
In conclusion, all the synthesized new 1,4-dihydropyridine derivatives (6a-6l) were found to be less potent than 
the standard cisplatin against the three cell lines tested. However, among them compounds 6j and 6l showed 
better activity compare to the other derivatives.  
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Table 2: Anticancer activity of new 1,4-dihydropyridine derivatives (6a-6l) 
COMPOUND 
 
-R R1 
IC50 (µM) 
MCF-7 HeLa Hep G2 
6a -C6H5 Cyclohexyl >100 87.8 96.4 
6b -C6H4. NO2 -3 Cyclohexyl 88.2 >100 >100 
6c -C6H4. OCH3 -4 Cyclohexyl 82.6 91.4 92.8 
6d -C6H4. CH3 -4 Cyclohexyl 93.5 86.3 >100 
6e -C6H4. Cl -4 Cyclohexyl 81.7 78.1 79.5 
6f -n-Pr Benzyl >100 >100 >100 
6g n-Bu Benzyl 86.2 >100 96.4 
6h -C6H5 Benzyl 84.5 >100 85.3 
6i -C6H4. NO2 -3 Benzyl 92.7 >100 95.8 
6j -C6H4. OCH3 -4 Benzyl 67.3 72.4 68.3 
6k -C6H4. CH3 -4 Benzyl 79.6 >100 75.4 
6l -C6H4. Cl -4 Benzyl 56.8 66.5 73.8 
Cisplatin 
  
12.7 9.3 13.8 
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